Charles Schwab Investment Management Inc. Purchases 13,922 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Charles Schwab Investment Management Inc. increased its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 23.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,427 shares of the company’s stock after purchasing an additional 13,922 shares during the period. Charles Schwab Investment Management Inc. owned about 0.20% of Lifecore Biomedical worth $553,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of LFCR. 272 Capital LP raised its stake in shares of Lifecore Biomedical by 511.1% in the 3rd quarter. 272 Capital LP now owns 143,480 shares of the company’s stock valued at $707,000 after buying an additional 120,002 shares in the last quarter. Geode Capital Management LLC increased its stake in Lifecore Biomedical by 10.3% in the third quarter. Geode Capital Management LLC now owns 597,685 shares of the company’s stock valued at $2,948,000 after acquiring an additional 55,703 shares during the period. BNP Paribas Financial Markets raised its position in Lifecore Biomedical by 2,640.5% in the third quarter. BNP Paribas Financial Markets now owns 54,399 shares of the company’s stock worth $268,000 after purchasing an additional 52,414 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Lifecore Biomedical during the third quarter worth about $207,000. Finally, Bank of New York Mellon Corp boosted its holdings in Lifecore Biomedical by 71.9% during the fourth quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock valued at $599,000 after purchasing an additional 33,690 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was acquired at an average cost of $5.74 per share, with a total value of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at $3,212,775.58. This represents a 3.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 32.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd.

Lifecore Biomedical Stock Up 2.8 %

Shares of NASDAQ:LFCR opened at $7.04 on Tuesday. The company’s fifty day moving average is $6.15 and its 200-day moving average is $6.22. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99. The company has a market capitalization of $260.66 million, a PE ratio of -12.57 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Equities research analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.